Date:	Oct 8 <sup>th</sup> ,	2023		
Your N	lame:	Clara So		
Manus	cript Title:	Identify	ing factors causing failure o	f nodal staging by endobronchial ultrasound-guided
transb	ronchial ne	edle aspiration	in non-small cell lung cance	
Manus	cript num	per (if known):	TLCR-23-264	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
_		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

None.

# Please place an "X" next to the following statement to indicate your agreement:

Date:	Oct 8th, 2	023		
Your Nam	ne: Y	uji Matsumoto	1	
Manuscri	pt Title:	Identifying f	actors causing failure of nodal stag	ing by endobronchial ultrasound-guided
<u>transbror</u>	nchial need	dle aspiration	in non-small cell lung cancer	
Manuscri	pt numbe	r (if known):	TLCR-23-264	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Japan Society for the Promotion of Science Hitachi, Ltd.	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5		Olympus	

	Payment or honoraria for	AstraZeneca
	lectures, presentations,	NOVARTIS
	speakers bureaus,	COOK
	manuscript writing or	AMCO
	educational events	Thermo Fisher Scientific
		Erbe Elektromedizin
		GmbH
		Fujifilm
		Chugai
		Eli Lilly
		Merck
		Takeda
		ETHICON
6	Payment for expert	X None
0	testimony	
	testimony	
7	Support for attending	XNone
· /	meetings and/or travel	
8	Patents planned, issued or	X None
Ŭ	pending	
	P 0.1.2.1.0	
0		
9	Participation on a Data	X_None
	Safety Monitoring Board or	
10	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	X_None
	financial interests	

The author receives grants for Medical Research from Japan Society for the Promotion of Science Hitachi, Ltd; and honoraria for lectures from Olympus, AstraZeneca, NOVARTIS, COOK, AMCO, Fisher Scientific, Thermo Erbe Elektromedizin GmbH, Fujifilm, Chugai, Eli Lilly, Merck, Takeda, and ETHICON.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: Oct 8th, 2023				
Your Name: <u>Tatsuya Imabayashi</u>				
Manuscript Title: <u>Identifying factors causing failure of nodal staging by endobronchial ultrasound-guided</u>				
transbronchial needle aspiration in non-small cell lung cancer				
Manuscript number (if known): TLCR-23-264				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present	XNone	
-	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	Hitachi High-Tech	
	any entity (if not indicated	Corporation	
	in item #1 above).		
2	Develties er liesness	V. Neze	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
5		СООК	Personal fees for lectures

	Payment or honoraria for	Chugai pharma	Personal fees for lectures
	lectures, presentations, speakers bureaus, manuscript writing or	Eli Lilly	Personal fees for lectures
		Thermo Fisher Scientific	Personal fees for manuscript writing
		K.K.	Personal lees for manuscript writing
	educational events	Olympus	Personal fees for lectures
		Novartis pharma	Personal fees for lectures
		Fujifilm	Personal fees for lectures
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	X_None	

The author receives grants from Hitachi High-Tech Corporation; and honoraria for lectures from COOK, Chugai pharma, Eli Lilly, Olympus, Novartis pharma, and Fujifilm; and honoraria for manuscript writing from Thermo Fisher Scientific K.K.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: Oct 8th	2023			
Your Name: Keigo Uchimura				
Manuscript Title: <u>Identifying factors causing failure of nodal staging by endobronchial ultrasound-guided</u>				
transbronchial needle aspiration in non-small cell lung cancer				
Manuscript number (if known): TLCR-23-264				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP22K15698 Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP19K16966	Grant for Medical Research Grant for Medical Research

3	Royalties or licenses	XNone	
4	Consulting fees	XNone	
5	Payment or honoraria for	Novartis	honoraria for lectures
	lectures, presentations,	Thermo Fisher Scientific	honoraria for lectures
	speakers bureaus, manuscript writing or	AstraZeneca	honoraria for lectures
	educational events	Chugai	honoraria for lectures
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

The author receives grants for Medical Research from Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number JP22K15698 and KAKENHI Grant Number JP19K16966; honoraria for lectures from Novartis, Thermo Fisher Scientific, AstraZeneca, and Chugai.

### Please place an "X" next to the following statement to indicate your agreement:

Date: Oct 8th, 2023			
Your Name: Yuichiro Ohe			
Manuscript Title:Identifying factors causing failure of nodal staging by endobronchial ultrasound-guided			
transbronchial needle aspiration in non-small cell lung cancer			
Manuscript numbe	er (if known): TLCR-23-264		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca Eli Lilly BMS Dainippon- Sumitomo Taiho Takeda Daiichi-Sankyo Chugai ONO		

		Kyorin
		Pfizer
		Novartis
		Kissei
		Janssen
3	Royalties or licenses	X None
4	Consulting fees	X None
-	consulting rees	
-	Devene entre a la caración fora	A - tur 7 - u
5	Payment or honoraria for	AstraZeneca
	lectures, presentations,	Chugai
	speakers bureaus,	Eli Lilly
	manuscript writing or	Bayer
	educational events	MSD
		Nippon Kayaku
		Kyowa Hakko Kirin
		Eisai
		ONO
		BMS
		Boehringer Ingelheim
		Pfizer
		Taiho
6	Payment for expert	X None
0	testimony	
	testimony	
7	Current for attanding	V Nama
7	Support for attending	XNone
_	meetings and/or travel	
8	Patents planned, issued or	XNone
	pending	
9	Participation on a Data	XNone
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	XNone
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11		Y Nono
11	Stock or stock options	XNone
12	Possint of aquinment	V Nono
12	Receipt of equipment,	XNone
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	

The author receives grants for Medical Research from AstraZeneca, Eli Lilly, BMS, Dainippon-Sumitomo, Taiho, Takeda, Daiichi-Sankyo, Chugai, ONO, Kyorin, Pfizer, Novartis, Kissei, and, Janssen; honoraria for lectures from AstraZeneca, Chugai, Eli Lilly, Bayer, MSD, Nippon Kayaku, Eisai, ONO, BMS, Boehringer Ingelheim, Pfizer, Taiho, and Kyowa Hakko Kirin.

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct 8 <sup>th</sup> , 2023			
Your Name: Hideaki Furuse			
Manuscript Title: Identifying factors causing failure of nodal staging by endobronchial ultrasound-guided	ł		
transbronchial needle aspiration in non-small cell lung cancer			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial	planning of the work
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
	Time frame: past	36 months
Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
Royalties or licenses	X_None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b> Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this   relationship or indicate   none (add rows as   needed)   Time frame: Since the initial   All support for the present   manuscript (e.g., funding,   provision of study materials,   medical writing, article   processing charges, etc.)   No time limit for this item.   Grants or contracts from   any entity (if not indicated   in item #1 above).

4	Consulting fees	XNone	
-	Deumont on housenin for	V Novo	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
	meetings and/or travel		
8	Patents planned, issued or	X_None	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.

Please place an "X" next to the following statement to indicate your agreement:

Date: Oct 8th, 2023			
Your Name: <u>Takaaki Tsuchida</u>			
Manuscript Title: <u>Identifying factors causing failure of nodal staging by endobronchial ultrasound-guided</u>			
transbronchial needle aspiration in non-small cell lung cancer			
Manuscript numb	er (if known):TLCR-23-264		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame. Since the finitian	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	XNone	
	Time frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	Japan Agency for Medical Research and Development	Grant for Medical Research
		Foundation for Promotion Cancer Research	Grant for Medical Research
		JSPS KAKENHI Grant	Grant for Medical Research
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Nippon Medical School Foundation	Degree Examination Review Committee
6	Payment for expert testimony	X_None	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Hamamatsu University School of Medicine	Safety Monitoring Board
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	X_None	

The author receives grants for Medical Research from Japan Agency for Medical Research and Development, Foundation for Promotion Cancer Research, and JSPS KAKENHI Grant; honoraria for Degree Examination Review Committee from Nippon Medical School Foundation; participation on Safety Monitoring Board in Hamamatsu University School of Medicine.

### Please place an "X" next to the following statement to indicate your agreement: